Addendum
Addendum to Commission A13-33 (enzalutamide)
Report documents
-
Addendum
Addendum to Commission A13-33 (enzalutamide)
Press releases
Enzalutamide: IQWiG assessed data subsequently submitted by the manufacturer
Now indication and hint of major added benefit for patients with metastatic prostate cancer
Additional information
Federal Joint Committee (G-BA)
2014-02-20 A G-BA decision was published.
Project details
- Project no.
- A14-06
- Commission
- Commission awarded on 23.01.2014 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed